Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

Lohse, 2016, Update of survival for persons with HIV infection in Denmark, Ann Intern Med, 165, 749, 10.7326/L16-0091 Lok, 2010, Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection, AIDS, 24, 1867, 10.1097/QAD.0b013e32833adbcf Beck, 2011, The cost-effectiveness of early access to HIV services and starting cART in the UK 1996–2008, PLoS ONE, 6, e27830, 10.1371/journal.pone.0027830 Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos con infección por el virus de la inmunodeficiencia humana (Actualización enero 2018). Available from: http://www.gesida-seimc.org/category/guias-clinicas/antirretroviral-vigentes/ [cited 09.02.18]. Rivero, 2017, Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults, Enferm Infecc Microbiol Clin, 10.1016/j.eimc.2016.06.013 Blasco, 2013, Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH), Enferm Infecc Microbiol Clin, 31, 568, 10.1016/j.eimc.2013.06.002 Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Boletín Oficial del Estado, no 126, (24.05.10). Consejo General de Colegios Oficiales de Farmacéuticos. Relación de presentaciones de medicamentos con precio notificado y financiados, de dispensación en oficina de farmacia, de uso hospitalario y de dispensación hospitalaria sin cupón precinto, y sus correspondientes laboratorios comercializadores, con precios notificados incluidos en el Nomenclátor de aplicación en el mes de FEBRERO de 2018. Available from: http://www.portalfarma.com/Profesionales/medicamentos/preciosmenores/precios-notificados/Paginas/Precios-Notificados.aspx [Cited 09.02.18]. Consejo General de Colegios Oficiales de Farmacéuticos. Portalfarma. Available from: https://botplusweb.portalfarma.com/ [Cited 09.02.18]. Gallant, 2017, Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial, Lancet, 390, 2063, 10.1016/S0140-6736(17)32299-7 Walmsley, 2013, Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection, N Engl J Med, 369, 18, 10.1056/NEJMoa1215541 Clotet, 2014, Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study, Lancet, 383, 31, 10.1016/S0140-6736(14)60084-2 Raffi, 2013, Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study, Lancet, 381, 735, 10.1016/S0140-6736(12)61853-4 ViiV Healthcare. E-mail correspondence with: Gatell JM (Department of Infectious Diseases and AIDS, Hospital Clinic-IDIBAPS, Barcelona, España). January 2013. Sax, 2017, Lancet, 390, 2073, 10.1016/S0140-6736(17)32340-1 Cahn, 2017, Raltegravir 1200mg once daily versus raltegravir 400mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial, Lancet HIV, 4, e486, 10.1016/S2352-3018(17)30128-5 Lennox, 2009, Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, Lancet, 374, 796, 10.1016/S0140-6736(09)60918-1 Eron, 2011, Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial, Lancet Infect Dis, 11, 907, 10.1016/S1473-3099(11)70196-7 Sax, 2015, Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, Lancet, 385, 2606, 10.1016/S0140-6736(15)60616-X Sax, 2012, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks, Lancet, 379, 2439, 10.1016/S0140-6736(12)60917-9 DeJesus, 2012, Lancet, 379, 2429, 10.1016/S0140-6736(12)60918-0 Squires, 2016, Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study, Lancet HIV, 3, e410, 10.1016/S2352-3018(16)30016-9 Eron, 2017 Ortiz, 2008, Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48, AIDS, 22, 1389, 10.1097/QAD.0b013e32830285fb Lennox, 2014, Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial Ann Intern Med. 2014;161 461–471, Erratum Ann Intern Med, 161, 680 Raffi, 2014, Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial, Lancet, 384, 1942, 10.1016/S0140-6736(14)61170-3 Molina, 2011, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial, Lancet, 378, 238, 10.1016/S0140-6736(11)60936-7 Cohen, 2014, Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults, AIDS, 28, 989, 10.1097/QAD.0000000000000169 van Lunzen, 2016, Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study, AIDS, 30, 251, 10.1097/QAD.0000000000000911 Sloan, 2012, Newer drugs and earlier treatment: impact on lifetime cost of care for HIV infected adults, AIDS, 26, 45, 10.1097/QAD.0b013e32834dce6e